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A liquid chromatography method for evaluating the stability of Nystatin (Nys) in an ointment was 
developed and validated, since the traditional pharmacopeial microbiological methods are unable to 
indicate stability. The stress experiments showed that Nys was found to significantly degrade in alkaline 
and acidic conditions and also under oxidative stress. Lower levels of degradation were detected under 
heat and with the sample exposed to Xenon light. Resolutions higher than 2 for Nys and degradation 
products (DP) chromatographic peaks were achieved by using an Inerstil ODS-3 column, isocratic elution 
with methanol:water and UV detection at 305 nm. The system was found to be linear over a range of 
102 to 310 IU mL-1 and proved precise, since the RSD(%) was 0.24% for the six replicates tested. The 
method also exhibited good levels of recovery (from 98.24% to 100.74%). Therefore, the validation 
fulfilled pharmacopeial requirements and the procedure was found to be reliable, precise, accurate and 
selective for determination of Nys and its degradation products.
Uniterms: Nystatin/stability analysis. Forced degradation/stress. High performance liquid 
chromatography/qualitative analysis.
Um método indicador de estabilidade por cromatografia líquida foi desenvolvido e validado para a 
análise de Nistatina (Nys) em uma pomada, uma vez que os métodos microbiológicos tradicionais não 
têm a habilidade de serem indicadores de estabilidade. A nistatina degradou significativamente em 
condições alcalinas e ácidas e também em meio oxidante. Quando a amostra foi exposta a luz de xenônio, 
foram observados menores níveis de degradação. A resolução entre os picos cromatográficos de Nys e 
seus produtos de degradação (PD) foi maior que 2, utilizando-se uma coluna Inerstil ODS-3, eluição 
isocrática com metanol: água e detecção no UV em 305 nm. O sistema foi linear entre a faixa de 102 a 
310 UI mL-1 e preciso uma vez que o DPR(%) foi de 0,24% entre as seis replicatas testadas. Além disso, 
o método exibiu bons níveis de recuperação (de 98,24% a 100,74%). Consequentemente, considera-se 
que a validação atendeu a todos os requisitos farmacopêicos e o método pode ser considerado confiável, 
preciso, exato e seletivo para determinação de Nys e seus produtos de degradação.
Unitermos: Nistatina/análise de estabilidade. Degradação forçada/estresse. Cromatografia líquida de 
alta eficiência/análise qualitativa.
INTRODUCTION
Nystatin is a substance, or a mixture of two or more 
substances (Figure 1), produced by the growth of Strep-
tomyces noursei (Streptomycetaceae). It has a potency 
of at least 4400 units per mg, or when intended for use in 
extemporaneous preparation, at least 5000 units per mg. 
Some physical chemistry characteristics of nystatin inclu-
FIGURE 1 – Chemical structure of nystatin.
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de: yellow to light tan, hygroscopic powder, with an odour 
suggestive of cereals, being affected by long-term exposure 
to light, heat and air. Nys is a polyene antifungal antibiotic 
used for the prophylaxis and treatment of candidiasis of the 
skin and mucous membranes (Martindale, 2002).
Pharmacopeial methods for Nys assay, as well for 
other antibiotics, are traditionally microbiological (USP, 
2008; EP, 2008) and yield the potency of the drug.
However, the use of microbiological methods is 
limited or not applicable when it becomes necessary to 
monitor the degradation of a drug product when submitted 
to stability studies, for example.
The regulatory agency (ANVISA) currently requi-
res that analytical methods employed for drug products 
should be stability-indicating methods (ANVISA RE 
01/05; ANVISA RE 899/03; Giannellini et al., 2005; 
Kumar et al., 2007; Munro et al., 2001), i.e., selective/
specific for detecting not only the main active principle 
but also the impurities and degradation products that may 
emerge during short (accelerated) or long-term stability 
studies (ANVISA RE 01/05). Indeed, the use of this kind 
of method is strongly recommended when the principle 
active is indicated as unstable in the specialized literature 
(Martindale, 2002; Merck Index, 2001).
It is important to note that the purpose of stability 
testing is to provide evidence on how the quality of a 
drug substance or drug product varies over time under 
the influence of a variety of environmental factors such as 
temperature, humidity and light. Stability testing permits 
the establishment of recommended storage conditions, 
retest periods, and shelf-lives (ICH, 2003).
Forced degradation, or stress testing, is carried out 
under harsher conditions than those used for accelerated 
stability testing. Laboratory procedures should cause the 
potential drug to degrade under specific conditions (acid 
and base hydrolysis, light/photostability, peroxide oxida-
tion and temperature).
Stability-indicating-methods (SIM) are satisfactorily 
developed during forced degradation tests, with the main 
objective of evaluating the purity of both main active 
principle and degradation products. The analytical method 
obtained in this way will be able to detect such substances 
wherever they appear during stability studies.
Additionally, quantitative determination of degra-
dation products can be done by using analytical standards 
when available. If these are unavailable, the determina-
tions by % area are acceptable or in other cases, collecting 
of peaks by preparative HPLC or identification by HPLC-
MS are valid.
Although several HPLC methods can be found 
in the literature for Nys analysis (Lavra, 2008; Llabot, 
2007; Matusch, 1994; Ostrosky-Zeichner, 2001), to date, 
no stability-indicating-methods for Nys determination in 
drug products have been described. The aim of this study 
was to establish an analytical method which is specific 
and selective for Nys analysis in a commercial ointment 
product. This method was duly validated according to 
ANVISA regulations (ANVISA RE 899/03).
EXPERIMENTAL
Reagents and solutions
Analytical grade HCl (Merck), Dichloromethane 
(Tedia), Sodium hydroxide (Nalgon) and Hydrogen pe-
roxide (Synth), and HPLC grade Methanol (Tedia), were 
used. Dilutions, when necessary, were made to the desired 
concentrations for use in sample preparations. All reagents 
used were of analytical grade while the solvents were of 
chromatographic purity.
Standard solution
A solution of analytical standard (Nystatin USP 
CRS, potency 5751 IU.mg-1) was prepared at 4083.21 IU 
mL-1 (calibration solution A) for calibration purposes (see 
Table I). Two solutions at around 200 IU mL-1 (calibra-
tion solutions B and C) were prepared to test the system 
suitability of the method. The solvent used for dilution 
was methanol.
Calibration curve
Dilutions from solution A were made to prepare 
calibration solutions (Table I).
Sample preparation
Extraction
Approximately 1.0 g of a commercial sample 
TABLE I - Calibration curve solutions









*final volume = 5 mL
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(100 000 IU g-1) was weighed and transferred to a volume-
tric flask of 50 mL. 5 mL of dichloromethane was added 
and the solution was homogenized. The volume was then 
completed with methanol and the final solution vortexed 
for 1 minute. This solution was filtered through a 0.45 mm 
PVDF filter. 1 mL was transferred to a volumetric flask of 
10 mL and the volume was made up with the diluent to be 
used in the forced degradation study.
Forced degradation sample preparation (Specificity 
Assay)
An aliquot of 1 mL of the extracted sample was 
transferred to a volumetric flask and the volume was com-
pleted with the stressing solution/diluent listed in Table II. 
The resultant samples were incubated in an oven at 60 oC 
or in a photostability chamber for up to 48 hours - aliquots 
from these samples were then analyzed by HPLC-DAD.
The main objective during the development of the 
chromatographic conditions was to achieve peak purity 
of Nys, i.e. to guarantee the selectivity of the analytical 
method for this active principle.
Chromatographic conditions
For Nys determination, an Agilent model 1100 HPLC 
device with DAD detection at 305 nm was used. The chro-
matographic column used was a Phenomenex Inertsil ODS 
- 3 – 100Å (250 x 4.6 x mm, 5 µm) in an oven at 40 °C. 
The mobile phase was constituted by methanol: water 
(75:25 v:v) and the flow rate was 1.0 mL min-1. The injection 
volume was 10 µL. The retention time of Nys was around 
7 minutes and the total run time was 15 minutes.
Validation
After the initial establishment of the chromatogra-
phic conditions, the pharmacopeial validation require-
ments were followed using system suitability, linearity, 
LoQ, precision (repeatability and intermediate precision), 
accuracy and robustness assays.
The isomers of Nys were forced to co-elute and 
quantification was based on a single chromatographic 
peak.
Data Evaluation and Statistical Analysis
Degradation products were monitored and reported 
based on HPLC area percent values. Statistical analysis 
was limited to arithmetic mean and relative standard de-
viation (RSD).
Control of Bias
Each sample was analyzed in duplicate and all data 
obtained was expressed as arithmetic mean, standard de-
viation and relative standard deviation.
RESULTS AND DISCUSSION
Specificity of forced degradation samples
The analysis of the placebo - prepared in the same 
manner as the commercial samples- under the proposed 
chromatographic conditions showed no interference to 
Nystatin retention time. Table III shows the results of the 
analysis of each stressed sample, after 24 and 48 hours.
The proposed chromatographic conditions yielded 
pure peaks of Nys and degradation products, since the 
purity factor given by the equipment software was higher 
than 980.
Figures 2 and 3 present representative chromatogra-
ms of the analytical standard of Nys and also of the acidic 
hydrolysis stressed sample, respectively. The retention 
TABLE II - Forced degradation samples
Stressing condition Stressing solution/diluent Incubation temperature/time exposure
Acid hydrolysis 0.1 mol L-1 HCl 60 oC/120 hours





 0.3% (v/v) 60 oC/120 hours
Light exposure Methanol Xenon lamp at 250 W m-2 attached to ID 65 filters
Heat exposure Methanol 60 oC/120 hours
TABLE III - Time of exposure of samples to forced degradation
Stressing 
Condition
Percentage of degradation (%)
Time of exposure
24 hours 48 hours
Acid hydrolysis 88.2 -




Light exposure 8.9 19.8
Heat exposure 47.3 -
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time of Nys was around 6.3 minutes. Due to the strong de-
gradation of Nys (almost 88%) in the stressed sample, the 
chromatographic peak is lower compared to the analytical 
standard. Other peaks at 3.2 min and 4.00 min were eviden-
ced, corresponding to the degradation products (DP) of Nys 
formed due to hydrolysis in acidic media. A higher level of 
degradation was also found in the alkaline hydroxide sample 
(100%). The sample exposed to peroxide stress achieved 
around 58% of degradation while those exposed to heat 
and Xenon light displayed 48% and 9% of degradation, 
respectively. These samples were considered suitable for the 
method development, since different degradation products 
at different levels were achieved.
System suitability
The RSD of six injections of solution C was lower 
than 2% and the comparison with the unique injection of 
solution C was also lower than 2%, indicating that the me-
thod is adequate. Also, the plates for the column (N) were 
higher than 2500 and the USP tailing was lower than 2.0.
Linearity
The linearity was tested in the concentration ran-
ge of 102 to 310 IU mL-1. The correlation coefficient 
determined by the best fit from least-squares treatment 
was = 0.99993. The response factor was constant at all 
concentration levels.
LoQ
LoQ was determined as the concentration in which 
the ratio signal noise (standard deviation calculation at 
baseline) and height of the chromatographic peak (signal) 
was around 10 which was found to be 10.21 IU mL-1.
Precision
Repeatability and intermediate precision
The precision of the method was evaluated based on 
the results of the analysis of six samples from analyst A 
at day 1 and the results from intermediate precision from 
FIGURE 2 - Chromatogram of a solution of analytical standard of Nystatin [205 IU.mL-1] (refer to Chromatographic Conditions).
FIGURE 3 - Chromatogram of acid hydrolysis sample after 24 hours of incubation (refer to Chromatographic Conditions).
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six other samples / analyst B at day 3.
The  va lues  demons t ra ted  by  the i r  means 
(104839 IU g-1 for repeatability and 105192 IU g-1 for 
intermediate precision, respectively) and relative standard 
deviations (RSDs, calculated from the results of the six 
samples and twelve samples, were lower than 2%) that 
the method can be considered precise.
Accuracy of the method
The accuracy of the method is the degree of confor-
mity of a measured or calculated value with its actual or 
specified value. Table IV shows the results of the accuracy 
(recovery) assay tested for three concentration levels of 
Nystatin spiked in placebo. 
Recovery results for all samples were within the 
95% to 105% range, which is considered acceptable ac-
cording to pharmacopeial and official guidelines (USP, 
2008; ANVISA RE 899/03).
Robustness
The robustness of the method was tested by al-
terations on flow, proportion of organic solvent in the 
mobile phase and temperature of the column. The mean 
results [IU mL-1] of two injections, RSD and recovery 
for each tested condition compared to a reference sample 
(injected in the initial chromatographic conditions) are 
shown in Table V.
The criteria were all accepted for this validation sta-
ge, since the RSD between the injections in each analytical 
condition were lower than 2% and the recovery values 
were within 95%-105%.
CONCLUSIONS
The results for linearity, selectivity, precision (re-
peatability and intermediate precision), accuracy and 
robustness of the method were acceptable according to 
pharmacopeias and official guidelines. Therefore, the 
analytical method proposed can be considered a specific 
and valid HPLC- Stability-indicating method for analysis 
of Nys and degradation products for application in quality 
control processes and stability studies.
TABLE IV - Percentage of recovery for Nystatin
Level (%) Nominal concentration of 
Nystatin (IU mL-1)
Determined concentration of 
Nystatin (IU mL-1)
Recovery
% Mean (%) ± s
80 164.7 165.5 100.5 100.7± 0.3
162.7 164.3 101.0
162.9 164.2 100.8
100 213.9 216.5 101.2 100.2 ± 1.0
214.5 215.0 100.2
214.4 212.8 99.3
120 254.6 251.8 98.9 98.2 ± 0.6
254.3 249.1 97.9
254.8 249.5 97.9
Mean (%) 99.7 ± 1.3
TABLE V - Robustness 
Parameter Nystatin [IU mL-1]
Mean RSD Recovery (%) *
Flow (0.8 mL.min-1) 107161 0.1 100.9
Flow 1.2 mL.min-1 106505 0.2 100.3
73 % methanol: 27% water 107005 0.1 100.8
77 % methanol: 23% water 107014 0.2 100.8
Column oven at 35 °C 106665 0.9 100.5
Column oven at 45 °C 107608 0.2 101.4
*reference sample [106155.70 IU mL-1] was considered 100% compared with the actual value.
A. P. P. Cione, M. J. Liberale, P. M. Silva310
REFERENCES
BRASIL, Agência Nacional de Vigilância Sanitária Resolução 
(ANVISA). Recomendação técnica Available at: 
<http://www.anvisa.gov.br/medicamentos/recomenda/
fotoestabilidade.pdf>. Accessed on: 21 oct. 2009.
BRASIL, Agência Nacional de Vigilância Sanitária Resolução 
(ANVISA). RE nº 899, de 29 de maio de 2003. Guia para 
a Validação de Métodos Analíticos e Bionalíticos. Diário 
Oficial da União Poder Executivo, Brasília, 02 de jun. 2003. 
Available at: <http://e-legis.anvisa.gov.br/leisref/public/
showAct.php?mode=PRINT_VERSION&id=15132>. 
Accessed on: 21 oct 2009.
BRASIL. Agência Nacional de Vigilância Sanitária Resolução 
(ANVISA). Resolução RE nº 1, de 29 de julho de 2005 Guia 
para a realização de estudos de estabilidade. Diário Oficial 
da União; Poder Executivo, Brasília, 01 de agosto de 2005. 
Available at: <http://e-legis.anvisa.gov.br/leisref/public/
showAct.php?id=18109&mode=PRINT_VERSION>. 
Accessed on: 21 oct. 2009.
EUROPEAN PHARMACOPOEIA. 6.ed. Strasbourg: Council 
of Europe, 2007. p.2534-2536.
GIANNELLINI, V.; SALVATORE, F.; BARTOLUCCI, G.; 
CORAN A. C.; BAMBAGIOTTI-ALBERTI M. A validated 
HPLC stability-indicating method for the determination of 
diacerhein in bulk drug substance. J. Pharm. Biom. Anal., 
v.39, n.3-4, p.776-780, 2005.
INTERNATIONAL CONFERENCE ON HARMONISATION. 
Q2(R1) Validation of Analytical Procedures: Text and 
Methodology. Available at: <http://www.ich.org/LOB/
media/MEDIA417.pdf>. Accessed on: 15 jun. 2009.
INTERNATIONAL CONFERENCE ON HARMONISATION. 
Q1A(R2) Stability Testing of New Drug Substances and 
Products. Available at: <http://www.ich.org/LOB/media/
MEDIA419.pdf>. Accessed on: 15 jun. 2009.
KUMAR V.; BHUTANI H.; SINGH S. ICH guidance in 
practice: Validated stability-indicating HPLC method for 
simultaneous determination of ampicillin and cloxacilin in 
combination drug products. J. Pharm. Biom. Anal., v.43, 
n.2, p.769-773, 2007.
LLABOT, J. M; ALLEMANDI D. A; MANZO, R. H; LONGHI, 
M. R. HPLC method for the determination of nystatin in 
saliva for application in clinical studies. J.Pharm. Biom. 
Anal., v.45, n.3, p.526-30.2007.
LAVRA, Z. M. M.; SONEGO, F.; SILVA, R. M. F.; MEDEIROS, 
F. P. M.; de. Rev. Bras. Cienc. Farm. [online] v.44, n.4 
[citado 2009-06-16], p. 637-643, 2008. Available at: <http://
www.scielo.br/scielo.php?script=sci_arttext&pid=S1516>. 
Accessed on: 15 jun. 2009.
THE MERCK INDEX: Encyclopedia of chemical, drugs and 
biologicals. 30.ed. New Jersey: Merck, 2001. p.9806.
MUNRO J. S.; WALKER T. A., Ranitidine hydrochloride: 
development of an isocratic stability-indicating high-
performance liquid chromatographic separation. J. 
Chromatogr., v.914, n.1-2 A, p.13-21, 2001.
OSTROSKI-ZEICHNER, L.; BAZEMORE, S.; PAETZNICK, 
V. L.; RODRIGUEZ, J. R.; CHEN, E.; WALLACE, T.; 
COSSUM, P.; REX, J. H. Differential antifungal activity os 
isomeric forms of Nystatin. Antimicrob. Agents Chemother., 
v.45, n.10, p.2781-786, 2001.
SAUER, B.; MATUSCH R. High-performance liquid 
chromatographic separations of Nystatin and their influence 
on the antifungal activity. J. Chromatogr. A, v.672, n.1-2, 
p.247-253, 1994.
SWEETMAN, S.C. (Ed.). Martindale. The complete drug 
reference. (35.ed.) London: Pharmaceutical Press, 2002. 
p.392.
UNITED STATES PHARMACOPEIA. 31.ed. Rockville: 
United States Pharmacopeial Convention, 2008. p.2787-
2788.
Received for publication on 24th June 2008
Accepted for publication on 19th October 2009
